Product Description
NTLA-5001 is a CRISPR/Cas9-engineered T cell receptor (TCR)-T cell therapy in development for the treatment of all genetic subtypes of acute myeloid leukemia (AML).
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: Orphan Drug - Acute Leukemia|Acute Myeloid Leukemia|Leukemia|Myeloid Leukemia *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Intellia
Company Location: Eastern America
Company CEO: John M. Leonard
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Myeloid Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05066165 |
ITL-5001-CL-001 | P2 |
Terminated |
Acute Myeloid Leukemia |
2022-07-21 |
2023-02-09 |
Primary Endpoints|Start Date|Treatments |